Nanomedicine - OmicsDI

Show results for

Unknown (6771)
Genomics (78)
Proteomics (33)
Transcriptomics (30)
Metabolomics (3)
Other (1)

Organisms

Andropogon gerardi (27)
Bacteria (27)
Canis lupus familiaris (27)
Clostridium perfringens (27)
Cnidaria (27)
Cricetulus griseus (27)
Eukaryota (27)
Fasciola (27)
Hepatitis B virus (27)
Human betaherpesvirus 5 (27)
Madurella mycetomatis (27)
Mesocricetus auratus (27)
Miscanthus x giganteus (27)
Mus musculus (27)
Mycobacterium tuberculosis (27)
Orthoflavivirus (27)
Panicum virgatum (27)
Platyhelminthes (27)
Pseudomonas aeruginosa AES-1R (27)
Rattus norvegicus (27)
Saccharomyces cerevisiae (27)
Schizosaccharomyces pombe (27)
Severe acute respiratory syndrome coronavirus 2 (27)
Shigella (27)
Sorghastrum nutans (27)
Mus musculus (26)
Homo sapiens (7)
Rattus norvegicus (4)
Caenorhabditis elegans (1)
Mus (1)

Organisms

Mus musculus (36)
Homo sapiens (7)
Rattus norvegicus (6)
Mus (1)
Aurantiochytrium sp. T66 (1)
Caenorhabditis elegans (1)

Repository

ENA (77)
geo (29)
pride (27)
iProX (6)
biostudies-arrayexpress (3)
MetaboLights (3)

Tissue

Epithelial cell (10)
Blood plasma (8)
Cell culture (4)
Colon (3)
Blood (1)
Blood serum (1)
Bone marrow (1)
Epithelial cell of uterus (1)
Fibroblast (1)
Ovarian surface epithelial cell (1)
Plant cell (1)
Primary cell (1)
Root (1)
Skin (1)
Uterus (1)

Disease

Colon cancer (3)
Breast cancer (2)
Malignant neoplasm of ovary (2)
Brain glioblastoma multiforme (1)
Cardiovascular system disease (1)
Melanoma (1)
Multiple myeloma (1)
Prostate cancer (1)
Uterine cancer (1)

Technology Type

Mass Spectrometry (27)
Bottom-up proteomics (7)
Mass spectrometry imaging (6)
Top-down proteomics (6)
Data-dependent acquisition (4)
Shotgun proteomics (3)
Mass spectrometry (2)
Gel-based experiment (2)
Mass spectrometry assay (1)
All-ion fragmentation (1)
Data-independent acquisition (1)
HDMSE (1)
MSE (1)
SWATH MS (1)

Instrument Platform

Liquid Chromatography MS - positive - reverse-phase (2)
Liquid Chromatography MS - negative - reverse-phase (2)
Liquid Chromatography MS - alternating - reverse phase (1)

Publication Date

2026 (22)
2025 (12)
2022 (10)
2024 (6)
2023 (4)
2020 (3)
2019 (3)
2009 (2)
2010 (1)
2008 (1)

Metabolite Name

Lehualide A (1)
Viminadione B (1)
Sterequinone A (1)
2,3-Dehydroillifunone (1)
Bungeiquinone (1)
Aquiledine (1)
Scutebarbatine I(rel) (1)
(+)-Almuheptolide B (1)
Urauchimycin A (1)
Adipostatin B (1)
Acutifolin palmitate (1)
17-Carboxygrindelic acid (1)
Sulcatin (1)
Norgraveoline (1)
Myricanene A (1)
3beta,23,28-Trihydroxy-12-oleanene 23-caffeate (1)
Coccinone C (1)
Coeloginanthrin (1)
N-Acetylaspidospermidine (1)
Caesaldekarin J (1)
1-(4-hydroxyphenyl)-7-phenyl-(6E)-hept-6-en-3-one (1)
Ixerisoside D (1)
Milolide I (1)
5-O-Desosaminylplatenolide I (1)
Kulokekahilide 2 (1)
Burttinonedehydrate (1)
Isooxoflaccidin (1)
Revandchinone 1 (1)
5,4'-Dihydroxy-3,6,3'-trimethoxy-7-prenyloxyflavone (1)
7,8-Dihydrokavain (1)

First Public Date

2026 (24)
2025 (16)
2024 (14)
2022 (8)
2023 (4)
2019 (3)
2017 (2)
2014 (2)
2021 (1)
2020 (1)
2018 (1)
2015 (1)

Study type

Transcription profiling by array (3)

Release Date

2022 (683)
2023 (647)
2021 (637)
2025 (578)
2018 (535)
2020 (517)
2017 (507)
2024 (506)
2019 (488)
2016 (423)
2015 (415)
2014 (320)
2013 (137)
2012 (131)
2026 (115)
2011 (60)
2010 (36)
2009 (21)
2008 (12)
2007 (2)
2006 (2)
2005 (2)

Lab affiliation

Michigan State University (3)
Strand Leader and Lloyd Sansom Chair Biomaterials Engineering and Nanomedicine Future Industries Institute I Building X – X1-10 Mawson Lakes Campus I GPO Box 2471 University of South Australia Adelaide, South Australia 5001 (2)
1Seer, Inc., Redwood City, CA 94065, USA; 4Center for Nanomedicine and Department of Anesthesiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115, USA (1)
CINVESTAV Unidad Irapuato (1)
DIPARTIMENTO DI MEDICINA, CHIRURGIA E ODONTOIATRIA "SCUOLAMEDICA SALERNITANA", University of Salerno (1)
Department of Biotechnology and Nanomedicine, SINTEF Industry, Trondheim 7034, Norway (1)
Department of Chemistry Michigan State University (1)
Department of Chemistry, Michigan State University, 578 S Shaw Lane, East Lansing, Michigan 48824, United States (1)
Department of Genetics and Molecular Biology, Cinvestav-IPN (1)
International Centre for Cancer Vaccine Science, University of Gdansk, Kladki 24, 80-822 Gdansk, Poland (1)
Laboratory of Biotechnology and Nanomedicine, Department of Cellular, Computational and Integrative Biology (CIBIO), University of Trento, Via Sommarive 9, 38123, Trento, Italy (1)
Michigan State University, Chemistry (1)
MichiganStateUniversity (1)
Nanomedicine and Nanotoxicology Group, Physics Institute of São Carlos, São Paulo University. Avenida Trabalhador São Carlense, 400, CEP13560970 (Brazil) Phone: (+55) 16 3373 8656, São Carlos – SP – Brazil. (1)
Nantong University, China (1)
National Engineering Research Center for Nanomedicine, Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology (1)
National Engineering Research Center for Nanomedicine, Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430074, China (1)
National Engineering Research Center for Nanomedicine, Key Laboratory of Molecular Biophysics of Ministry of Education, College of Life Science and Technology, Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, 430074, China. (1)
Novo Nordisk Foundation Center for Biosustainability Technical University of Denmark Kemitorvet, DK-2800 Lyngby, Denmark (1)
Strand Leader and Lloyd Sansom Chair Biomaterials Engineering and Nanomedicine Future Industries Institute I Building X – X1-10 Mawson Lakes Campus I GPO Box 2471 (1)
Strand Leader and Lloyd Sansom Chair Biomaterials Engineering and Nanomedicine Future Industries Institute I Building X – X1-10 Mawson Lakes Campus I GPO Box 2471 University of South Australia (1)
Strand Leader and Lloyd Sansom Chair Biomaterials Engineering and Nanomedicine Future Industries Institute I Building X – X1-10 Mawson Lakes Campus I GPO Box 2471 University of South Australia Adelaide, South Australia 5001 t: +61 8 830 25563 | m: +61 434 079 108 f: +61 8 830 25639 (1)
Strand Leader and Lloyd Sansom Chair Biomaterials Engineering and Nanomedicine University of South Australia (1)
University College Dublin, School of Biomolecular and Biomedical Science, Conway Institute Belfield Dublin 4 (1)

Previous page
1 / 692
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 692
Next page

Sort by:

Relevance

Page size

Untargeted LC–MS serum metabolomics in a colitis mouse model treated with the microbiota-regulating nanomedicine MRA@RP

This study applies untargeted liquid chromatography–mass spectrometry (LC–MS)–based serum metabolomics to characterize metabolic alterations in a dextran sulfate sodium–induced colitis mouse model and to evaluate the therapeutic effects of the microbiota-regulating nanomedicine MRA_RP. Serum samp...

2025-11-22 | MTBLS13367 | MetaboLights

Ni-MOFs as a Simple and Effective Nanomedicine for ROS-Mediated Antibacterial Wound Healing via a Themoelectrocatalytic Process

Thermoelectrocatalytic nickel-based metal-organic frameworks (Ni-MOFs) autonomously generate reactive oxygen species (ROS) via human body-ambient temperature differences. They exhibit potent antibacterial activity against wound-infecting pathogens, and effectively promote infected skin wound heal...

2026-03-13 | MTBLS14045 | MetaboLights

Mass spectrometry-based top-down proteomics in nanomedicine: proteoform-specific measurement of protein corona

Conventional mass spectrometry (MS)-based bottom-up proteomics (BUP) analysis of protein corona [i.e., an evolving layer of biomolecules, mostly proteins, formed on the surface of nanoparticles (NPs) during their interactions with biomolecular fluids] enabled nanomedicine community to partly identif...

ORGANISM(S): Homo sapiens (Human)

2024-10-15 | PXD050779 | Pride

Spatial Transcriptomics-based Identification of Molecular Markers for Nanomedicine Distribution in Tumor Tissue

PRJNA805228 | ENA

Analysis of multi-drug cancer nanomedicine.

Not available

S-EPMC12373501 | biostudies-literature

Spatial Transcriptomics-based Identification of Molecular Markers for Nanomedicine Distribution in Tumor Tissue

To elucidate the factors that determine nanomedicine tumor uptake, we developed a molecular marker identification platform by integrating microscopic fluorescence images of nanomedicine distribution with spatial transcriptomics (ST) information. When this approach is applied to PEGylated liposomes, ...

ORGANISM(S): Mus musculus

2024-08-04 | GSE196506 | GEO

The big picture on nanomedicine: the state of investigational and approved nanomedicine products.

Not available

S-EPMC4467093 | biostudies-literature

Bioresponsive Polymers for Nanomedicine-Expectations and Reality!

Not available

S-EPMC9460233 | biostudies-literature

Selective targeting of visceral adiposity by polycation nanomedicine

PRJNA862525 | ENA

Imaging Nanomedicine-Based Drug Delivery: a Review of Clinical Studies.

Not available